Acute toxicity in 260 patients with locally limited prostate cancer after conformal radiotherapy risk-adjusted up to 74 Gy:: Results of a multicenter phase-II study

被引：0
|
作者：
Zimmermann, F
Geinitz, H
Wachter, S
Wachter-Gerstner, N
Goldner, G
Glocker, S
Feldmann, HJ
Becker, G
Bamberg, M
Pötter, R
Molls, M
机构：
[1] Tech Univ Munich, Klin Strahlentherapie & Radiol Onkol, D-8000 Munich, Germany
[2] Univ Vienna, Klin Strahlentherapie & Biol, Vienna, Austria
[3] Univ Klin Tubingen, Abt Strahlentherapie Radiol, D-72074 Tubingen, Germany
[4] Klinikum Fulda, Klin Radioonkol Strahlentherapie, Fulda, Germany
[5] Klin Eichert Goppingen, Onkol Klin, Strahlentherapie Radiol Zent Inst, Goppingen, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2002年 / 178卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：21 / 21
页数：1
相关论文
共 40 条
  • [31] Moderate risk-adapted dose escalation with three-dimensional conformal radiotherapy of localized prostate cancer from 70 to 74 Gy : FFFirst report on 5-year morbidity and biochemical control from a prospective Austrian-German multicenter phase II trial [Dreidimensionale konformale risikoadaptierte Radiotherapie des lokalisierten Prostatakarzinoms mit moderater Dosiseskalation von 70 auf 74 Gy. 5-Jahres-Resultate der prospektiven österreichisch-deutschen Phase-II-Multicenterstudie]
    Goldner G.
    Bombosch V.
    Geinitz H.
    Becker G.
    Wachter S.
    Glocker S.
    Zimmermann F.
    Wachter-Gerstner N.
    Schrott A.
    Bamberg M.
    Molls M.
    Feldmann H.
    Pötter R.
    Strahlentherapie und Onkologie, 2009, 185 (2) : 94 - 100
  • [32] LONG-TERM RESULTS OF A PROSPECTIVE, PHASE II STUDY OF LONG-TERM ANDROGEN ABLATION, PELVIC RADIOTHERAPY, BRACHYTHERAPY BOOST, AND ADJUVANT DOCETAXEL IN PATIENTS WITH HIGH-RISK PROSTATE CANCER
    DiBiase, Steven J.
    Hussain, Arif
    Kataria, Ritesh
    Amin, Pradip
    Bassi, Sunakshi
    Dawson, Nancy
    Kwok, Young
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (03): : 732 - 736
  • [33] Toxicity and Patient Reported Quality of Life after PSMAPET and mpMRT-Based Focal Dose Escalated Definitive Radiotherapy in Prostate Cancer Patients: 2-Year Follow-Up of the HypoFocal Phase II Trial
    Spohnfr, S. K. B.
    Gainey, M.
    Kamps, M.
    Jilg, C. A.
    Gratzke, C.
    Sigle, A.
    Mix, M.
    Ruf, J.
    Buerkle, S.
    Sprave, T.
    Wiehle, R.
    Serpa, M.
    Benndorf, M.
    Zschaeck, S.
    Ghadjar, P.
    Baltas, D.
    Kirste, S.
    Zamboglou, C.
    Grosu, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S95 - S95
  • [34] Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy prior to radical prostatectomy for patients with high risk localized prostate cancer: Pathologic outcomes and 3-year follow-up analyses
    Gleave, Martin E.
    Chi, Kim
    Chin, Joseph L.
    Winquist, Eric
    Klotz, Laurence H.
    Berry, Scott
    Ruether, Dean
    Trachtenberg, John
    Moore, Malcolm
    JOURNAL OF UROLOGY, 2007, 177 (04): : 377 - 377
  • [35] Combined Long-Term Androgen Deprivation and Pelvic Radiotherapy in the Post-operative Management of Pathologically Defined High-Risk Prostate Cancer Patients: Results of the Prospective Phase II McGill 0913 Study
    Kucharczyk, Michael Jonathan
    Tsui, James Man Git
    Khosrow-Khavar, Farzin
    Bahoric, Boris
    Souhami, Luis
    Anidjar, Maurice
    Probst, Stephan
    Chaddad, Ahmad
    Sargos, Paul
    Niazi, Tamim
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [36] Stereotactic body radiotherapy (SBRT) versus conventional fractionated intensity-modulated radiotherapy (CF-IMRT) for patients with early-stage localized prostate cancer: One-year late toxicity results from a prospective randomized phase II study.
    Poon, Darren M. C.
    Lam, Daisy
    Wong, Kenneth C. W.
    Chu, C. M.
    Mo, Frankie
    Suen, Joyce
    Ng, Chi-Fai
    Chan, Anthony T. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCaP): Pathologic outcomes and 3-year follow-up analyses
    Winquist, E.
    Chi, K. N.
    Chin, J.
    Goldenberg, L.
    Klotz, L.
    Berry, S.
    Saad, F.
    Perrotte, P.
    Ruether, D.
    Trachtenberg, J.
    Gleave, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Multicenter German/French phase-II trial of induction chemotherapy (CTx) followed by hyper-fractionated accelerated thoracic radiotherapy (HA-RTx) concurrent with CTx ± surgery (S) in locally advanced inoperable non-small-cell lung cancer (NSCLC) stage III patients -: mature results of a novel induction CTx regimen
    Eberhardt, W
    Le Pechoux, C
    Gauler, T
    Korfee, S
    Grunenwald, D
    Pöttgen, C
    Stamatis, G
    Fischer, B
    Trenn, G
    Le Chevalier, T
    Stuschke, M
    LUNG CANCER, 2004, 46 : S40 - S41
  • [39] Final overall survival (OS) analysis of a multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-RT) without elective nodal irradiation with chemotherapy using cisplatin (CDDP) and vinorelbine (VNR) in patients with stage III non-small cell lung cancer (NSCLC).
    Horinouchi, Hidehito
    Sekine, Ikuo
    Sumi, Minako
    Soejima, Toshinori
    Satouchi, Miyako
    Nagakura, Hisayasu
    Isobe, Hiroshi
    Nishiyama, Noriaki
    Harada, Masao
    Ishizuka, Naoki
    Tamura, Tomohide
    Ohe, Yuichiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Concomitant chemo-radiotherapy with oral vinorelbine and cisplatin after induction chemotherapy with cisplatin-docetaxel in patients with locally advanced non-small cell lung cancer: a multicenter phase II trial. GFPC study 05-03 (French cooperative group of thoracic oncology)
    Robinet, Gilles
    Fournel, Pierre
    Berard, Henri
    Falchero, Lionel
    Kahlout, Sana
    Monnet, Isabelle
    Chouabe, Stephane
    Geriniere, Laurence
    Bota, Suzanna
    Locher, Chrystele
    Thomas, Pascal
    Chajara, Abdesslam
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S861 - S861
1234